Avaliação e elucidação do mecanismo de ação de polímeros naturais modificados utilizados na agricultura / Evaluation and mode of action elucidation for modified natural polymers used in agriculture

Atualmente a agricultura ocupa um papel de extrema importância na conjuntura global e nacional e está inserida em um contexto de enormes desafios devido ao aumento da população mundial e maior demanda por alimentos. Ao mesmo tempo, é o setor mais afetado pelos impactos negativos das mudanças climáticas, que têm espalhado suas consequências de maneira cada vez mais frequente e intensa. Um dos principais efeitos é a alteração do regime de chuvas ao redor do globo, ocasionando estiagens intensas e duradouras, capazes de reduzir a produtividade de safras e comprometer a produção alimentícia. As abordagens atualmente existentes no mercado para mitigar as consequências negativas da escassez hídrica demandam alto investimento de implementação e manutenção, ou possuem um perfil ecotoxicológico insatisfatório. Polímeros de origem natural modificados quimicamente foram avaliados em termos de desempenho e capacidade de prover às plantas uma maior disponibilidade de água através de retenção hídrica. Os resultados alcançados demonstraram que os polímeros modificados com grupos iônicos foram capazes de promover um melhor gerenciamento hídrico no microambiente ao redor de sementes e entregar ganhos de produtividade a lavouras de soja. O mecanismo de ação da tecnologia estudada foi elucidado através de ensaios de determinação de capacidade de campo, análise de elipsometria, microscopia de força atômica, ensaios de germinação de soja sob estresse hídrico e implementação de áreas de soja a céu aberto a partir da aplicação em tratamento de sementes e sulco de plantio. As interações intra e intermoleculares entre as partículas de solo, moléculas de polímero e de água se mostraram ponto chave para a mudança de patamar de desempenho de polímeros naturais modificados utilizados na agricultura, quando comparados com os grupos controle. A tecnologia aqui estudada é, portanto, recomendada para utilização na agricultura, com capacidade de potencializar o efeito de tecnologias dependentes de água, resultando em maior produtividade na colheita

Nowadays agriculture occupies an extremely important role both in the global and national scenarios. Its included in a very challenging context due to the forecast of increased world population and consequent higher demand for food. At the same time, it is the most affected economic sector by the climate change effects, which have been causing frequent and harsh impacts. One of the main effects is the change in the rainfall pattern worldwide, which causes severe and long-lasting droughts, responsible for causing crops to fail and therefore putting food production at risk. The current available mitigation measures to address hydric scarcity require a huge investment for implementation and maintenance or do not present a satisfactory and safe ecotoxicological profile. Chemically modified natural polymers have been evaluated in terms of performance and ability to provide the plants with higher water availability through hydric retention. The results obtained show that such ionic group modified polymers are able to promote better water management in a given microenvironment surrounding the seeds and ultimately delivery a higher yield to soy crops. The technology's mode of action has been elucidated through field capacity determination trials, ellipsometry, atomic force microscopy, soy germination trials under hydric stress and, finally, implementation of soy areas under actual field conditions by applying the polymers via seed treatment and in-furrow methods. Both intra- and intermolecular interaction between soil particles, polymer and water molecules have been proven as key to understanding the agricultural performance improvement of the modified polymers when compared to the control. The technology is recommended for agricultural applications due to its ability to boost the effect of water-dependent technologies, promoting higher yields

Tempos de atendimento e desfechos no infarto agudo do miocárdio com supradesnivelamento ST / Time of care and outcomes in ST-segment elevation myocardial infarction

Objetivo: Comparar os tempos de tratamento dor-porta e porta-balão em indivíduos com infarto agudo do miocárdio com supradesnivelamento ST com os desfechos cardiovasculares em 30 dias. Métodos: Trata-se de uma coorte histórica, realizada por meio da pesquisa de prontuários eletrônicos e dos bancos de dados já existentes dos serviços de hemodinâmica de todos os indivíduos atendidos com diagnóstico de infarto agudo do miocárdio com supradesnivelamento ST e submetidos à angioplastia, no período de março de 2015 a setembro de 2016, em dois hospitais públicos de grande porte de Porto Alegre (RS). Os desfechos foram o óbito intra-hospitalar e em 30 dias e os eventos cardíacos maiores hospitalares e em 30 dias. Resultados: Foram avaliadas as informações de 808 indivíduos, sendo 26,9% provenientes do Hospital de Clínicas de Porto Alegre e 73,1% do Instituto de Cardiologia ­ Fundação Universitária de Cardiologia. Não houve diferença significativa na caracterização da amostra. Um terço dos indivíduos analisados apresentou tempo dor- -porta menor ou igual a 180 minutos, e 72% tiveram tempo porta-balão menor que 90 minutos. A mediana do tempo total de isquemia foi de 338 minutos. Na avaliação dos tempos não houve diferença significativa entre os dois hospitais. Para eventos cardíacos maiores e óbitos intra- -hospitalares, o único tempo que se mostrou significativo, após o ajuste multivariado, foi o porta-balão, em que os indivíduos com tempo maior que 90 minutos apresentaram razão de risco de 1,06 (IC95% 1,02-1,11) e 5,78 (IC95% 1,44-23,2), respectivamente, para eventos cardíacos maiores e óbitos intra-hospitalares. Para eventos cardíacos maiores total e óbito total, nenhum dos três tempos se associou significativamente com o desfecho após ajuste. Contudo, o tempo porta-balão maior ou igual a 90 minutos também foi significativo para razão de risco bruto para ambos, assim como a dor-porta para óbito total. Conclusão: Os dados da pesquisa corroboram as recomendações internacionais para cumprimento dos menores tempos de atendimento, em especial do tempo porta-balão, para o bom prognóstico. Infelizmente, no país, o tempo de isquemia miocárdica ainda está muito aquém do ótimo, necessitando de melhorias na área para melhorar os desfechos nesses indivíduos.

Objective: To compare symptom-onset-to-door and door- -to-balloon times in individuals with ST-segment elevation myocardial infarction to the 30-day cardiovascular outcomes. Methods: This is a historical cohort, using electronic medical records and the existing databases of hemodynamic services of all individuals diagnosed with ST-segment elevation myocardial infarction undergoing angioplasty between March 2015 and September 2016, in two large public hospitals in Porto Alegre. The outcomes were in-hospital death and death in 30 days, and major adverse cardiac events in hospital and in 30 days. Results: The information of 808 patients was evaluated, with 26.9% from Hospital de Clínicas de Porto Alegre, and 73.1% from the Instituto de Cardiologia ­ Fundação Universitária de Cardiologia. There was no significant difference in the characterization of the sample. One-third of the individuals evaluated presented symptom-onset-to-door of 180 minutes or less, and 72% had door-to- -balloon time below 90 minutes. The median total ischemic time was 338 minutes. In the evaluation of the times, there was no significant difference between the two hospitals. For more major cardiac events and intra-hospital deaths, the only time that proved to be significant after the multivariate adjustment was the door-to-balloon time, in which individuals with time higher than 90 minutes had a risk ratio of 1.06 (95% CI 1.02-1.11) for major cardiac events and 5.78 (95% CI 1.44-23.2), for intra-hospital deaths. For total major adverse cardiac events and total death, none of the 3 times was significantly associated with the outcome after adjustment; however, door-to-balloon of 90 minutes or more was also significant for crude risk ratio for both, as well as symptom-onset-to-door for total death. Conclusion: The research data corroborate the international recommendations to meet shorter service times, especially door-to-balloon time, for a good prognosis. Unfortunately, in the country, the time of myocardial ischemia is still far from optimal, requiring improvement in the area to improve the outcomes in these individuals.

Impacto na qualidade de vida em pacientes usuários de medicação retroviral e submetidos à gluteoplastia: estudo de coorte histórica / Gluteal contour restoration in antiretroviral users and its quality-of-life related impacts: a historical cohort study

INTRODUÇÃO: Desde a introdução do tratamento do HIV com uso da terapia antirretroviral altamente ativa, a mortalidade por essa doença foi reduzida drasticamente em todo o mundo. Um dos parefeitos relacionados à utilização desses fármacos é a lipodistrofia glútea. O objetivo deste trabalho é verificar o impacto da correção dessa deformidade na qualidade de vida de pacientes com HIV. MÉTODOS: Foi conduzido um estudo de coorte histórica com 23 pacientes submetidos à gluteoplastia com implante intramuscular, entre janeiro de 2010 e dezembro de 2014, avaliando a qualidade de vida por meio do em Nottingham Health Profile em. As informações foram coletadas de julho a agosto de 2015. A análise estatística foi feita utilizando-se o em Related-Samples McNemar Test em. RESULTADOS: strong Houve diferença significativa entre o pré-operatório e pós-operatório em 19 das 38 perguntas. CONCLUSÃO: É possível afirmar que a reconstrução glútea melhora a qualidade de vida de pacientes HIV positivos acometidos por lipodistrofia glútea relacionada a antirretrovirais.

INTRODUCTION: Since the introduction of highly active antiretroviral therapy for the treatment of human immunodeficiency virus (HIV), disease mortality has been dramatically reduced worldwide. One related side effect from the use of these drugs is gluteal lipodystrophy. The aim of this study is to assess the quality-of-life impact of correcting this deformity in HIV patients. METHODS: A historical cohort study was conducted between January 2010 and December 2014 with 23 patients, assessing the quality of their lives using the Nottingham Health Profile. A statistical analysis was performed using the McNemar test for related samples. RESULTS: There was a significant difference between preoperative and postoperative response in 19 of the 38 questions. CONCLUSION: We may say that gluteal reconstruction plays a role in improving quality of life for HIV patients who have been affected by antiretroviral related gluteal lipodystrophy.

Eficácia da ciclosporina no controle da dermatite atópica em cães / Efficacy of cyclosporine in the control of atopic dermatitis in dogs

A dermatite atópica é uma dermatopatia inflamatória, pruriginosa, crônica, de origem genética, resultante da perda da função de barreira física da pele e da hiperreatividade à alérgenos ambientais, trofoalérgenos, alérgenos microbianos e a irritantes primários. Este estudo avaliou a eficácia da ciclosporina no controle do prurido e das lesões associadas à dermatite atópica em cães. Selecionaram-se 24 cães com diagnóstico de dermatite atópica baseados nos critérios de Favrot et al. (2010), os quais foram divididos em dois grupos de 12 cães, onde o Grupo 1, recebeu ciclosporina (5mg/kg/vo/24h), e o Grupo 2, foi tratado com prednisona (0,5mg/kg/vo/24h) em doses decrescentes, ambos por 60 dias. Os animais foram continuamente avaliados, e seus escores sintomato-lesionais, baseados na escala de CADESI-03, estabelecidos nos dias 0, 30 e 60. Em adição, os escores de prurido de cada animal, baseado nos critérios de Rybnicek, foram semanalmente avaliados, do dia 0 ao 63. Todos os dados coletados foram analisados pelo teste não paramétrico de Kruskal-Wallis, seguido do teste de Dunn´s e para as análises entre os grupos foi utilizado o teste t, considerado o nível de significância mínimo de 5%. A ciclosporina teve uma eficácia similar, no controle lesional, ao grupo que recebeu prednisona no dia (+30) (p<0,05) e no dia (+60) (p<0,001) do tratamento, em relação ao dia zero. Uma diferença significativa do escore do prurido foi observada nos dias +28, +35, +42, +49, +56 e +63 (p<0,001), e no dia +21 (p<0,01) em relação ao momento inicial do tratamento, porém sua eficácia foi inferior ao Grupo 2, a partir do 42º dia de avaliação, mantendo-se esta diferença nos dias +49, +56 e +63 (p>0,05). Apesar da ciclosporina ter sido menos eficaz no controle do prurido, este se manteve em níveis aceitáveis, e seu uso contínuo não foi associado a efeitos colaterais relevantes.(AU)

Atopic dermatitis is an itchy, chronic inflammatory skin disease of genetic origin, resulting from loss of the physical barrier function of the skin and hyper-reactivity to environmental allergens, trofoallergens, microbial allergens and to primary irritants. The efficacy of cyclosporine in the control of pruritus and lesions associated with atopic dermatitis in dogs was evaluated. Twenty-four dogs with atopic dermatitis were selected, based on Favrot et al.'s criteria (2010). They were divided into two groups of 12 dogs, where Group 1 received cyclosporine (5mg/kg/vo/24h), and Group 2 was treated with prednisone (0.5mg/kg/vo/24h) in decreasing doses, both for 60 days. The animals were continuously evaluated, and theirits lesional symptomatology scores were based on a Cadesi-03 scale, set on days 0, 30 and 60. Pruritus scores of each dog, based on Rybnicek´s criteria, were weekly evaluated, from day 0 to day 63. All collected data were analyzed by the nonparametric Kruskal-Wallis´ test, followed by Dunn's test, and for the analysis between the groups, considered the minimum significance level of 5%, t-test was used. Cyclosporin had similar efficacy in lesional control in the group which received prednisone on day (+30) (p<0.05) and on the day (+60) (p<0.001) of treatment, compared with day zero. A significant difference of the itching score was observed on days +28, +35, +42, +49, +56 and +63 (p<0.001), and on day +21 (p<0.01) when compared to initial treatment. However, its efficacy was lower than Group 2, from 42 days of evaluation on, keeping such difference on days +49, +56 and +63 (p>0.05). Although cyclosporin have been less effective in controlling itching, it remained at acceptable levels, and its continued use was not associated with significant side effects.(AU)

Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update.

BACKGROUND: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents. OBJECTIVES: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009. METHODS: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations. RESULTS: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment. CONCLUSION: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice.

Incidence and factors associated with pericardial effusion after cardiac valve surgery

Introduction: Pericardial effusion (PE) is a postoperative complication of cardiac valve surgery, related to early hospital readmissions and death. We aimed to describe its incidence and to identify predictive factors of moderate-to-severe PE in a contemporary cohort. Methods: We retrospectively reviewed medical records of all consecutive patients submitted to cardiac valve surgery in a tertiary teaching hospital from January 2012 to July 2014, where echocardiography was routinely performed before patient discharge. Moderate-to-severe PE was defined as ≥ 10 mm of thickness, or signs of cardiac tamponade on echocardiography. Additional clinical and perioperative data were extracted from medical records using a standardized protocol. Results: Of 353 patients, 335 underwent a predischarge echocardiography. From these, 27 patients (8%; mean age: 62 years; standard deviation 12 years; 70% male) had moderate-to-severe PE. These patients had a higher prevalence of previous stroke (22% vs. 8%; p = 0.009) and oral anticoagulation (international normalized ratio > 2) prior to the surgery (11 vs. 2%; P = 0.002). In patients with moderate-to-severe PE, surgeries had longer ischemia (p < 0.001) and cardiopulmonary bypass (p < 0.001) times, and the prevalence of postoperative atrial fibrillation was higher (56% vs. 32%; p = 0.011) than in patients with absent or small PE. Hospital mortality was also higher (15% vs. 3%; p = 0.002) in patients with moderate-to-severe PE. Conclusions: Eight percent of patients submitted to cardiac valve surgery developed moderate-to-severe PE. Moreover, PE was associated with pre- and post-surgery conditions likely related to the coagulation state, though a cause-effect relationship could not be inferred. Noteworthy, this condition was associated with higher in-hospital morbidity and mortality(AU)

O impacto de ações assistenciais na percepção da qualidade do Sistema Único de Saúde (SUS), Brasil: um estudo transversal / The impact of care actions on the perception of the quality of the Single Health System (SUS), Brazil: a cross-sectional study

INTRODUÇÃO: O tumor de pele não melanoma é o câncer mais frequente no Brasil. A ressecção cirúrgica é um dos pilares do manejo e ações assistenciais como mutirões de cirurgias são formas de reduzir o tempo de espera por tratamento. MÉTODOS: Nesse trabalho, conduziu-se um estudo transversal com 40 pacientes, 20 deles participantes de mutirão e 20 controles. Coletaram-se dados epidemiológicos, além de nove perguntas relacionadas à qualidade do Sistema Único de Saúde (SUS). RESULTADOS: Observou-se diferença significativa entre as respostas relacionadas ao tempo de espera por cirurgias no SUS (p < 0,05). CONCLUSÃO: Pode-se verificar melhora na impressão dos pacientes em relação ao SUS quando incluídos em ações assistenciais.

INTRODUCTION: Non-melanoma skin cancer is the most prevalent cancer in Brazil. Surgical resection is one of the pillars of management, and care actions, such as surgical task forces, are one way to reduce treatment waiting time. METHODS: In this research, we conducted a cross-sectional study with 40 patients; 20 of whom were treated by a surgical task force and 20 were controls. Epidemiological data were collected in addition to answers to nine questions related to the quality of the Single Health System (SUS in Portuguese). RESULTS: A significant difference was observed in responses related to the waiting time for surgery in the SUS (p < 0.05). CONCLUSION: One can observe an improvement in the perception of patients, with regard to the SUS, when included in care actions.

PORTUGUESE RECOMMENDATIONS FOR THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS--2015 UPDATE.

OBJECTIVE: To update recommendations for the treatment of psoriatic arthritis with biological therapies, endorsed by the Portuguese Society of Rheumatology (SPR). METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. At a national meeting the 16 recommendations included in this document were discussed and updated. The level of agreement among Portuguese Rheumatologists was assessed using an online survey. A draft of the full text of the recommendations was then circulated and suggestions were incorporated. A final version was again circulated before publication. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with psoriatic arthritis (PsA). Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. CONCLUSION: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis.

OBJECTIVE: To develop recommendations for the treatment of psoriatic arthritis (PsA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. METHODS: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. At a national meeting the recommendations were discussed and all attending rheumatologists voted on the level of agreement for each recommendation. A second draft was again circulated before publication. RESULTS: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with PsA. Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. CONCLUSION: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.

Relationship between plasma glucose levels and malignant uterine cervical neoplasias.

BACKGROUND: There is a direct correlation between glycemic load and the risk of developing many malignant neoplasms. AIMS: The aim of this study was to determine the plasma glucose levels in women with cervical cancer. METHODS: The study included 177 women with anatomopathologically diagnosed uterine cervical cancer (stages 0-IV) treated between 1980 and 2008 at the Gynecology and Obstetrics outpatient service of the UFTM, Brazil. The plasma glucose levels of all patients were assayed at the time of diagnosis and correlated with tumor staging. RESULTS: We statistically compared the plasma glucose levels of group 1 (cervical intraepithelial neoplasia 2-3), group 2 (stage I-II), group 3 (stage III-IV), and group 4 (control group: leiomyomas). Patient groups with poor prognosis (groups 2 and 3) showed significantly higher plasma glucose levels (P < 0.05) than those with less aggressive lesions (group 1). Plasma glucose levels were significantly higher in groups 2 and 3 than in group 4 (P < 0.05). The comparison of number of patients with plasma glucose level >90 mg/dl showed CIN versus I/II: P = 0.0753; OR = 2.018; (95% CI: 0.9236 to 4.410) and CIN versus III/IV: P = 0.0975; OR = 2.400; (95% CI: 0.8335 to 6.911). CONCLUSION: We observed an association between high plasma glucose levels and cervical cancer cases with poor prognoses. Plasma glucose tests should be routinely used as additional prognostic parameters in patients with cervical neoplasias.

Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update.

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of Rheumatoid Arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of nonresponders. Biological treatment (with a tumour necrosis factor antagonist, abatacept or tocilizumab) should be considered in RA patients with a disease activity score 28 (DAS 28) equal to or greater than 3.2 despite treatment with at least 20mg-weekly-dose of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 3 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, defined by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of at least 0.6 in the DAS28 score. After 6 months of treatment res­ponse criteria is defined as a decrease greater than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab).

Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update.

The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment should be considered in RA patients with a disease activity score 28 (DAS 28) superior to 3.2 despite treatment with 20mg/week of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 6 months of other conventional disease modifying drug or combination therapy. A DAS 28 score between 2.6 and 3.2 with a significant functional or radiological deterioration under treatment with conventional regimens could also constitute an indication for biological treatment. The treatment goal should be remission or, if that is not achievable, at least a low disease activity, characterized by a DAS28 lower than 3.2, without significative functional or radiological worsening. The response criteria, at the end of the first 3 months of treatment, are a decrease of 0.6 in the DAS28 score. After 6 months of treatment response criteria is defined as a decrease of more than 1.2 in the DAS28 score. Non-responders, in accordance to the Rheumatologist's clinical opinion, should try a switch to another biological agent (tumour necrosis factor antagonist, abatacept, rituximab or tocilizumab).